These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 36588166

  • 1. Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.
    Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B.
    J Bone Miner Res; 2023 Apr; 38(4):464-470. PubMed ID: 36588166
    [Abstract] [Full Text] [Related]

  • 2. Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
    Leder BZ, Zapalowski C, Hu MY, Hattersley G, Lane NE, Singer AJ, Dore RK.
    J Bone Miner Res; 2019 Dec; 34(12):2213-2219. PubMed ID: 31411768
    [Abstract] [Full Text] [Related]

  • 3. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D.
    Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
    [Abstract] [Full Text] [Related]

  • 4. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
    Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS.
    J Clin Endocrinol Metab; 2020 Mar 01; 105(3):938-43. PubMed ID: 31674644
    [Abstract] [Full Text] [Related]

  • 5. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.
    Watts NB, Dore RK, Baim S, Mitlak B, Hattersley G, Wang Y, Rozental TD, LeBoff MS.
    Osteoporos Int; 2021 Jan 01; 32(1):55-61. PubMed ID: 32935170
    [Abstract] [Full Text] [Related]

  • 6. Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.
    Greenspan SL, Fitzpatrick LA, Mitlak B, Wang Y, Harvey NC, Deal C, Cosman F, McClung M.
    Menopause; 2020 Oct 01; 27(10):1137-1142. PubMed ID: 32665529
    [Abstract] [Full Text] [Related]

  • 7. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C.
    Osteoporos Int; 2017 Oct 01; 28(10):2967-2973. PubMed ID: 28748386
    [Abstract] [Full Text] [Related]

  • 8. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
    Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG.
    J Clin Endocrinol Metab; 2018 Aug 01; 103(8):2949-2957. PubMed ID: 29800372
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
    Lewiecki EM, Czerwinski E, Recknor C, Strzelecka A, Valenzuela G, Lawrence M, Silverman S, Cardona J, Nattrass SM, Binkley N, Annett M, Pearman L, Mitlak B.
    J Bone Miner Res; 2023 Oct 01; 38(10):1404-1414. PubMed ID: 37417725
    [Abstract] [Full Text] [Related]

  • 10. Contributions of Clinical and Technical Factors to Longitudinal Change in Trabecular Bone Score and Bone Density: A Registry-Based Individual-Level Analysis.
    Leslie WD, Goel H, Binkley N, McCloskey EV, Hans D.
    J Bone Miner Res; 2023 Apr 01; 38(4):512-521. PubMed ID: 36655775
    [Abstract] [Full Text] [Related]

  • 11. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 12. Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend.
    Deal CL, Mitlak BH, Wang Y, Fitzpatrick LA, Miller PD.
    Bone Rep; 2019 Dec 16; 11():100230. PubMed ID: 31799340
    [Abstract] [Full Text] [Related]

  • 13. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
    Miller PD, Bilezikian JP, Fitzpatrick LA, Mitlak B, McCloskey EV, Cosman F, Bone HG.
    Curr Med Res Opin; 2020 Nov 16; 36(11):1861-1872. PubMed ID: 32969719
    [Abstract] [Full Text] [Related]

  • 14. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
    Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M.
    Calcif Tissue Int; 2017 Oct 16; 101(4):396-403. PubMed ID: 28589205
    [Abstract] [Full Text] [Related]

  • 15. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
    Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D.
    Mayo Clin Proc; 2017 Feb 16; 92(2):200-210. PubMed ID: 28160873
    [Abstract] [Full Text] [Related]

  • 16. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F.
    Osteoporos Int; 2019 Jun 16; 30(6):1187-1194. PubMed ID: 30899994
    [Abstract] [Full Text] [Related]

  • 17. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
    Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbini CAF, Wang Z, Oates MK, Recknor C, Libanati C.
    J Bone Miner Res; 2021 Nov 16; 36(11):2139-2152. PubMed ID: 34190361
    [Abstract] [Full Text] [Related]

  • 18. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.
    Hans D, McDermott M, Huang S, Kim M, Shevroja E, McClung M.
    Osteoporos Int; 2023 Jun 16; 34(6):1075-1084. PubMed ID: 36862192
    [Abstract] [Full Text] [Related]

  • 19. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
    Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, Binkley N, Lewiecki EM, Adachi J, Knychas D, Kendler D, Orwoll E, Chen Y, Pearman L, Li YH, Mitlak B.
    J Bone Miner Res; 2022 Dec 16; 37(12):2435-2442. PubMed ID: 36190391
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.